Mutational heterogeneity in cancer and the search for new cancer-associated genes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Major international projects are underway that are aimed at creating a comprehensive catalogue of all the genes responsible for the initiation and progression of cancer. These studies involve the sequencing of matched tumour-normal samples followed by mathematical analysis to identify those genes in which mutations occur more frequently than expected by random chance. Here we describe a fundamental problem with cancer genome studies: as the sample size increases, the list of putatively significant genes produced by current analytical methods burgeons into the hundreds. The list includes many implausible genes (such as those encoding olfactory receptors and the muscle protein titin), suggesting extensive false-positive findings that overshadow true driver events. We show that this problem stems largely from mutational heterogeneity and provide a novel analytical methodology, MutSigCV, for resolving the problem. We apply MutSigCV to exome sequences from 3,083 tumour-normal pairs and discover extraordinary variation in mutation frequency and spectrum within cancer types, which sheds light on mutational processes and disease aetiology, and in mutation frequency across the genome, which is strongly correlated with DNA replication timing and also with transcriptional activity. By incorporating mutational heterogeneity into the analyses, MutSigCV is able to eliminate most of the apparent artefactual findings and enable the identification of genes truly associated with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The reproducibility of scientific findings has been called into question.”
From Evaluating replicability of laboratory experiments in economics (2016) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Melanoma has one of the highest rates of mutation of any cancer16.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [16]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Cancer cells are genetically unstable, which contributes to their uncontrolled proliferation and the expression of antigens that can be recognized by the immune system.”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Self-citationAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 2×
“…(GBM) 2 and lung adenocarcinoma 1,4 ; CSMD3 in ovarian cancer 2 ; PCLO in diffuse large B-cell lymphoma (DLBCL) 9 ; MUC16 in lung squamous carcinoma 11 , breast cancer 12 and DLBCL 8 ; MUC4 in melanoma 13 ; olfactory receptor OR2L13 in GBM 14 ; and TTN in breast cancer 12 and other tumor types 15 .”
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Self-citationPatterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 1×
“…genes have already cropped up in recently published cancer genome studies, for example: LRP1B in glioblastoma (GBM) 2 and lung adenocarcinoma 1,4 ; CSMD3 in ovarian cancer 2 ; PCLO in diffuse large B-cell lymphoma (DLBCL) 9 ; MUC16 in lung squamous carcinoma 11 , breast cancer 12 and DLBCL 8…”
Self-citationThe Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,504 · cited 2×
“Recent studies have also implicated HPV in head-and-neck cancers 5 .”
InfluentialSelf-citationMutational Processes Molding the Genomes of 21 Breast Cancers
Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.024 · Cited by 1,909 · cited 3×
“Recent work 19,20 has shown that the TpC mutations tend to occur in proximity to one another, consistent with the activity of APOBEC enzymes in damaged long single-strand DNA regions.”
Influential
Cited by
Items 901–1,000 of 1,039
Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review
Heppt, M. V., Steeb, T., Schlager, J. G., Rosumeck, S., Dressler, C., Ruzicka, T., Nast, A., & Berking, C. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.009 · Cited by 107
Emerging trends in the immunotherapy of pancreatic cancer
Banerjee, K., Kumar, S., Ross, K. A., Gautam, S. K., Poelaert, B. J., Nasser, M. W., Aithal, A., Bhatia, R., Wannemuehler, M. J., Narasimhan, B., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.12.012 · Cited by 116
Anker, J. F., Naseem, A. F., Mok, H., Schaeffer, A. J., Abdulkadir, S. A., & Thumbikat, P. (2018) · Nature Communications · doi:10.1038/s41467-018-03900-x · Cited by 113
Tanaka, Y., Chiwaki, F., Kojima, S., Kawazu, M., Komatsu, M., Ueno, T., Inoue, S., Sekine, S., Matsusaki, K., Matsushita, H., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00240-6 · Cited by 111
AACR Project GENIE: 100,000 Cases and Beyond
Pugh, T. J., Bell, J. L., Bruce, J. P., Doherty, G. J., Galvin, M., Green, M. F., Hunter-Zinck, H., Kumari, P., Lenoue-Newton, M. L., Li, M. M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1547 · Cited by 106
Self-citationTumour-wide RNA splicing aberrations generate actionable public neoantigens
Kwok, D. W., Stevers, N. O., Etxeberría, I., Nejo, T., Cove, M. C., Chen, L. H., Jung, J., Okada, K., Lakshmanachetty, S., Gallus, M., et al. (2025) · Nature · doi:10.1038/s41586-024-08552-0 · Cited by 116
“Even if a proportion of the neojunctions was expressed in the entire tumor in at least one case, and some in at least two or more cases, the authors should provide calculations indicating the minimal and average numbers of neojunctions required to cover all the tumor cells, in a certain fraction of…”
Medulloblastoma: Molecular Classification-Based Personal Therapeutics
Archer, T. C., Mahoney, E. L., & Pomeroy, S. L. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0526-y · Cited by 117
Stemming the Rising Incidence of Melanoma: Calling Prevention to Action
Gershenwald, J. E., & Guy, G. P. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv381 · Cited by 115
An, Ö., Dall’Olio, G. M., Mourikis, T. P., & Ciccarelli, F. D. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1123 · Cited by 114
Mutation signatures implicate aristolochic acid in bladder cancer development
Poon, S. L., Huang, M. N., Choo, Y., McPherson, J. R., Yu, W., Heng, H. L., Gan, A., Myint, S. S., Siew, E. Y., Ler, L. D., et al. (2015) · Genome Medicine · doi:10.1186/s13073-015-0161-3 · Cited by 109
Hajirasouliha, I., Mahmoody, A., & Raphael, B. J. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu284 · Cited by 124
Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity
Tan, H., Bao, J., & Zhou, X. (2015) · Scientific Reports · doi:10.1038/srep12566 · Cited by 109
The Ecology and Evolution of Cancer: The Ultra-Microevolutionary Process
Wu, C., Wang, H., Ling, S., & Lu, X. (2016) · Annual Review of Genetics · doi:10.1146/annurev-genet-112414-054842 · Cited by 118
Self-citationGenomic landscape of ovarian clear cell carcinoma via whole exome sequencing
Kim, S. I., Lee, J. W., Lee, M., Kim, H. S., Chung, H. H., Kim, J., Park, N. H., Song, Y. S., & Seo, J. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.12.005 · Cited by 121
Self-citationRaynaud, F., Mina, M., Tavernari, D., & Ciriello, G. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007669 · Cited by 109
The Role of Immunotherapy in Pancreatic Cancer
Mukherji, R., Debnath, D., Hartley, M. L., & Noel, M. S. (2022) · Current Oncology · doi:10.3390/curroncol29100541 · Cited by 116
Functional variomics and network perturbation: connecting genotype to phenotype in cancer
Yi, S., Lin, S., Li, Y., Zhao, W., Mills, G. B., & Sahni, N. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.8 · Cited by 97
Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies
Park, J. A., & Cheung, N.-K. V. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.006 · Cited by 103
Genetics of metastasis: melanoma and other cancers
Turner, N., Ware, O. R., & Bosenberg, M. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9893-y · Cited by 110
Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review
Al-Jundi, M., Thakur, S., Gubbi, S., & Kłubo-Gwieździńska, J. (2020) · Cancers · doi:10.3390/cancers12082104 · Cited by 111
Heinrich, S., Craig, A. J., Ma, L., Heinrich, B., Greten, T. F., & Wang, X. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.036 · Cited by 115
Liu, Z., Zhang, Y., Shi, C., Zhou, X., Xu, K., Jiao, D., Sun, Z., & Han, X. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02697-y · Cited by 138
Kennedy, A. L., Vallurupalli, M., Chen, L., Crompton, B. D., Cowley, G. S., Vázquez, F., Weir, B. A., Tsherniak, A., Parasuraman, S., Kim, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4903 · Cited by 115
Self-citationVersatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation
Braun, C. J., Bruno, P. M., Horlbeck, M. A., Gilbert, L. A., Weissman, J. S., & Hemann, M. T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600582113 · Cited by 101
Wagener, R., Seufert, J., Raimondi, F., Bens, S., Kleinheinz, K., Nagel, I., Altmüller, J., Thiele, H., Hübschmann, D., Kohler, C. W., et al. (2018) · Blood · doi:10.1182/blood-2018-07-864025 · Cited by 104
The Stress-Like Cancer Cell State Is a Consistent Component of Tumorigenesis
Baron, M., Tagore, M., Hunter, M. V., Kim, I. S., Moncada, R., Yan, Y., Campbell, N. R., White, R. M., & Yanai, I. (2020) · Cell Systems · doi:10.1016/j.cels.2020.08.018 · Cited by 106
Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities
Eddy, K., Shah, R., & Chen, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.626129 · Cited by 120
Vandeveer, A. J., Fallon, J. K., Tighe, R., Sabzevari, H., Schlom, J., & Greiner, J. W. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0176 · Cited by 107
Genome-wide analysis of somatic noncoding mutation patterns in cancer
Dietlein, F., Wang, A. B., Fagre, C. R., Tang, A., Besselink, N. J. M., Cuppen, E. P. J. G., Li, C., Sunyaev, S. R., Neal, J. T., & Allen, E. M. V. (2022) · Science · doi:10.1126/science.abg5601 · Cited by 123
“5 of the materials and methods): coding regions [regions with the most mutations in exons or splice sites in exon-intron boundaries and findings detected by MutSigCV (3) or dNdScv (4)]; regulatory regions [regions with the most mutations inH3K4me3 or H3K27ac ChIP-seq peaks from Roadmap (7)]; tissue-specific genes (mut…”
InfluentialSelf-citationThe genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
Vo, J. N., Wu, Y., Mishler, J., Hall, S., Mannan, R., Wang, L., Yu, N., Zhou, J. R., Hopkins, A. C., Estill, J. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31430-0 · Cited by 110
Self-citationGenomic and immune landscape Of metastatic pheochromocytoma and paraganglioma
Calsina, B., Piñeiro-Yáñez, E., Martínez‐Montes, Á. M., Caleiras, E. J., Fernández-Sanromán, Á., Monteagudo, M., Torres‐Pérez, R., Torre, C. F., Pulgarín-Alfaro, M., Gil, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36769-6 · Cited by 126
Vedeld, H. M., Andresen, K., Eilertsen, I. A., Nesbakken, A., Seruca, R., Gladhaug, I. P., Thiis‐Evensen, E., Rognum, T. O., Boberg, K. M., & Lind, G. E. (2014) · International Journal of Cancer · doi:10.1002/ijc.29039 · Cited by 107
The genomic landscape of testicular germ cell tumours: from susceptibility to treatment
Litchfield, K., Levy, M., Huddart, R. A., SHIPLEY, J. M., & Turnbull, C. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.107 · Cited by 113
Cytotoxic CD8+ Lymphocytes in the Tumor Microenvironment
Iwahori, K. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-35723-8_4 · Cited by 108
An extended APOBEC3A mutation signature in cancer
Langenbucher, A., Bowen, D., Sakhtemani, R., Bournique, E., Wise, J. F., Zou, L., Bhagwat, A. S., Buisson, R., & Lawrence, M. S. (2021) · Nature Communications · doi:10.1038/s41467-021-21891-0 · Cited by 114
Self-citationTherapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials
Sobhani, N., Scaggiante, B., Morris, R. M., Chai, D., Catalano, M., Tardiel-Cyril, D. R., Neeli, P. K., Roviello, G., Mondani, G., & Li, Y. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102429 · Cited by 107
Bailey, S. D., Desai, K., Kron, K. J., Mazrooei, P., Sinnott-Armstrong, N., Treloar, A. E., Dowar, M., Thu, K. L., Cescon, D. W., Silvester, J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3650 · Cited by 104
Self-citationZheng, P., Li, J., & Kros, J. M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21463 · Cited by 108
Wang, G., Chow, R. D.-W., Ye, L., Guzman, C. D., Dai, X., Dong, M. B., Zhang, F., Sharp, P. A., Platt, R. J., & Chen, S. (2018) · Science Advances · doi:10.1126/sciadv.aao5508 · Cited by 103
Ferrara, R., Imbimbo, M., Malouf, R. S., Paget‐Bailly, S., Calais, F., Marchal, C., & Westeel, V. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013257.pub3 · Cited by 124
Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots
Jalili, P., Bowen, D., Langenbucher, A., Park, S., Aguirre, K., Corcoran, R. B., Fleischman, A. G., Lawrence, M. S., Zou, L., & Buisson, R. (2020) · Nature Communications · doi:10.1038/s41467-020-16802-8 · Cited by 99
Self-citationSu, X., Hu, P., Li, D., Zhao, B.-W., Niu, Z., Herget, T., Yu, P. S., & Hu, L. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01312-5 · Cited by 115
“Computational approaches in the first category achieve identification tasks on the basis of original multi-omics data of genes 13,14 .”
APOBEC3B mutagenesis in cancer
Kuong, K. J., & Loeb, L. A. (2013) · Nature Genetics · doi:10.1038/ng.2736 · Cited by 110
Ohba, K., Ichiyama, K., Yajima, M., Gemma, N., Nikaido, M., Wu, Q., Chong, P. P., Mori, S., Yamamoto, R., Wong, J. E. L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097787 · Cited by 110
Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma
Krumbholz, M., Hellberg, J., Steif, B., Bäuerle, T., Gillmann, C., Fritscher, T., Agaimy, A., Frey, B., Juengert, J., Wardelmann, E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3028 · Cited by 96
Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations
In, G. K., Hu, J. S., & Tseng, W. W. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017712963 · Cited by 112
Immune checkpoint inhibitors for metastatic bladder cancer
Massari, F., Nunno, V. D., Cubelli, M., Santoni, M., Fiorentino, M., Montironi, R., Cheng, L., López-Beltrán, A., Battelli, N., & Ardizzoni, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.007 · Cited by 107
Zhu, H., Uusküla-Reimand, L., Isaev, K., Wadi, L., Alizada, A., Shuai, S., Huang, V., Aduluso-Nwaobasi, D., Paczkowska, M., Abd-Rabbo, D., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2019.12.027 · Cited by 101
Discovering the drivers of clonal hematopoiesis
Pich, O., Reyes-Salazar, I., Gonzalez-Perez, A., & Lopez-Bigas, N. (2022) · Nature Communications · doi:10.1038/s41467-022-31878-0 · Cited by 96
Lee, S., Huh, J. Y., Turner, D. M., Lee, S., Robinson, J., Stein, J. E., Shim, S. H., Hong, C. P., Kang, M. S., Nakagawa, M., et al. (2018) · Stem Cells · doi:10.1002/stem.2865 · Cited by 99
Cancer systems biology of TCGA SKCM: Efficient detection of genomic drivers in melanoma
Guan, J., Gupta, R., & Filipp, F. V. (2015) · Scientific Reports · doi:10.1038/srep07857 · Cited by 94
Correa, B. R., de Araujo, P. R., Qiao, M., Burns, S. C., Chen, C., Schlegel, R., Agarwal, S., Galante, P. A. F., & Penalva, L. O. F. (2016) · Genome Biology · doi:10.1186/s13059-016-0990-4 · Cited by 101
Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation
Yu, L., Kim, H. T., Kasar, S. N., Benien, P., Du, W., Hoang, K., Aw, A., Tesar, B., Improgo, R., Fernandes, S. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0594 · Cited by 95
“Driver Genes in Del(17p) CLL To identify driver genes in del(17p) CLL, we ran the MutSigCV algorithm(30) on the 53 del(17p) CLL in our WES cohort.”
MethodSelf-citationKeung, E. Z.-Y., Lazar, A. J., Torres, K. E., Wang, W.-L., Cormier, J. N., Guadagnolo, B. A., Bishop, A. J., Lin, H. Y., Hunt, K. K., Bird, J. E., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4829-0 · Cited by 102
Epigenetic Regulators as the Gatekeepers of Hematopoiesis
Rodrigues, C. P., Shvedunova, M., & Akhtar, A. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.09.015 · Cited by 107
Chmielecki, J., Bailey, M., He, J., Elvin, J. A., Vergilio, J., Ramkissoon, S. H., Suh, J. H., Frampton, G. M., Sun, J., Morley, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1106 · Cited by 102
Self-citationLi, Q. K., Pavlovich, C. P., Zhang, H., Kinsinger, C. R., & Chan, D. W. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.004 · Cited by 109
Schweizer, M. T., Ha, G., Gulati, R., Brown, L. C., McKay, R. R., Dorff, T. B., Hoge, A. C. H., Reichel, J. B., Vats, P., Kilari, D., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00383 · Cited by 113
Lamble, A. J., Kosaka, Y., Laderas, T., Maffit, A., Kaempf, A. J., Brady, L., Wang, W., Long, N., Saultz, J. N., Mori, M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916206117 · Cited by 102
Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance
Hossain, S. M., & Eccles, M. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021601 · Cited by 101
Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer
Harris, R. S. (2015) · Breast Cancer Research · doi:10.1186/s13058-014-0498-3 · Cited by 103
BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features
Neuendorff, N. R., Burmeister, T., Dörken, B., & Westermann, J. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2721-z · Cited by 107
Lo, J. A., Kawakubo, M., Juneja, V. R., Su, M. Y., Erlich, T. H., LaFleur, M. W., Kemeny, L. V., Rashid, M., Malehmir, M., Rabi, S. A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd8636 · Cited by 97
Self-citationThe SIOPE strategic plan: A European cancer plan for children and adolescents
Vassal, G., Schrappe, M., Pritchard‐Jones, K., Arnold, F., Basset‐Salom, L., Biondi, A., Bode, G., Eggert, A., Hjorth, L., Kamerić, L., et al. (2016) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2016.03.007 · Cited by 97
Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
Findlay, J. M., Castro-Giner, F., Makino, S., Rayner, E., Kartsonaki, C., Cross, W., Kovac, M., Ulahannan, D., Palles, C., Gillies, R. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms11111 · Cited by 94
Zhang, T., Xie, J., Arai, S., Wang, L., Shi, X., Shi, N., Ma, F., Chen, S., Huang, L., Yang, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12230 · Cited by 91
Transcriptional landscape of human cancers
Li, M., Sun, Q., & Wang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.15837 · Cited by 101
Chen, C., Bai, L., Cao, F., Wang, S., He, H., Song, M., Chen, H., Liu, Y., Guo, J., Si, Q., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0735-4 · Cited by 104
The Mutational Features of Aristolochic Acid–Induced Mouse and Human Liver Cancers
Lu, Z., Luo, Q., Zhao, L., Shi, Y. Y., Wang, N., Wang, L., & Han, Z. (2019) · Hepatology · doi:10.1002/hep.30863 · Cited by 102
Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
Casadei, C., Dizman, N., Schepisi, G., Cursano, M. C., Basso, U., Santini, D., Pal, S. K., & Giorgi, U. D. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919890285 · Cited by 101
Hirsch, T. Z., Pilet, J., Morcrette, G., Roehrig, A., Monteiro, B. J. E., Molina, L. M., Bayard, Q., Trépo, E., Meunier, L., Caruso, S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1809 · Cited by 100
Therapeutic Targeting of DNA Damage Response in Cancer
Choi, W., & Lee, E. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031701 · Cited by 105
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics
de Waal, L., Lewis, T. A., Rees, M. G., Tsherniak, A., Wu, X., Choi, P. S., Gechijian, L., Hartigan, C., Faloon, P. W., Hickey, M. J., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.1984 · Cited by 96
Self-citationOkada, N., Kawazoe, H., Takechi, K., Matsudate, Y., Utsunomiya, R., Zamami, Y., Goda, M., Imanishi, M., Chuma, M., Hidaka, N., et al. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.11.004 · Cited by 96
Massively parallel phenotyping of coding variants in cancer with Perturb-seq
Ursu, O., Neal, J. T., Shea, E., Thakore, P. I., Jerby-Arnon, L., Nguyen, L., Dionne, D., Diaz, C., Bauman, J., Mosaad, M. M., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01160-7 · Cited by 96
Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights
Ng, C. K. Y., Schultheis, A. M., Bidard, F., Weigelt, B., & Reis-Filho, J. S. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv015 · Cited by 112
Identification of an Immunogenic Subset of Metastatic Uveal Melanoma
Rothermel, L. D., Sabesan, A. C., Stephens, D. J., Chandran, S. S., Paria, B. C., Srivastava, A. K., Somerville, R. P. T., Wunderlich, J. R., Lee, C. R., Xi, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2294 · Cited by 102
EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions
Sasaki, S., Nishikawa, J., Sakai, K., Iizasa, H., Yoshiyama, H., Yanagihara, M., Shuto, T., Shimokuri, K., Kanda, T., Suehiro, Y., et al. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0880-4 · Cited by 104
Integrative genomic analysis of mouse and human hepatocellular carcinoma
Dow, M. T., Pyke, R. M., Tsui, B., Alexandrov, L. B., Nakagawa, H., Taniguchi, K., Seki, E., Harismendy, O., Shalapour, S., Karin, M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811029115 · Cited by 99
“Across human cohorts, MutSigCV (37) identified 13 genes with higher-than-expected mutation rates: TP53, CTNNB1, AXIN1, ALB, BAP1, EEF1A1, NFE2L2, RPS6KA3, CDKN2A, RB1, ACVR2A, KEAP1, and ARID1A.”
MethodInfluentialHendriks, L. E. L., Rouleau, É., & Besse, B. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.22 · Cited by 104
Identifying Epistasis in Cancer Genomes: A Delicate Affair
van de Haar, J., Canisius, S., Yu, M., Voest, E. E., Wessels, L. F. A., & Ideker, T. (2019) · Cell · doi:10.1016/j.cell.2019.05.005 · Cited by 99
Epigenetic dysregulation of KCa3.1 channels induces poor prognosis in lung cancer
Bulk, E., Ay, A., Hammadi, M., Ouadid‐Ahidouch, H., Schelhaas, S., Hascher, A., Rohde, C., Thoennissen, N. H., Wiewrodt, R. G., Schmidt, E., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29490 · Cited by 110
The Emerging Genomic Landscape of Endometrial Cancer
Gallo, M. L., & Bell, D. W. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.205740 · Cited by 96
Lee, T.-Y., Huang, K.-Y., Chuang, C.-H., Lee, C.-Y., & Chang, T.-H. (2020) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2020.107277 · Cited by 95
Berland, L., Heeke, S., Humbert, O., Macocco, A., Long-Mira, E., Lassalle, S., Lespinet-Fabre, V., Lalvée, S., Bordone, O., Cohen, C., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.11.102 · Cited by 95
Vettore, A. L., Ramnarayanan, K., Poore, G. D., Lim, K. J., Ong, C. K., Huang, K. K., Leong, H. S., Chong, F. T., Lim, T. K., Lim, W. K., et al. (2015) · Genome Medicine · doi:10.1186/s13073-015-0219-2 · Cited by 100
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
Carlo, M. I., Voss, M. H., & Motzer, R. J. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.103 · Cited by 97
Recurrent PDGFRB mutations in unicentric Castleman disease
Li, Z., Lan, X., Li, C., Zhang, Y., Wang, Y., Xue, W., Lu, L., Jin, M., Zhou, Z., Wang, X., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0323-6 · Cited by 95
Tumor mutational burden in lung cancer: a systematic literature review
Willis, C., Fiander, M., Tran, D., Korytowsky, B., Thomas, J.-M., Calderon, F., Zyczynski, T. M., Brixner, D. I., & Stenehjem, D. D. (2019) · Oncotarget · doi:10.18632/oncotarget.27287 · Cited by 102
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
Klemen, N. D., Wang, M., Rubinstein, J. C., Olino, K. L., Clune, J. E., Ariyan, S., Cha, C. H., Weiss, S. A., Kluger, H. M., & Sznol, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000341 · Cited by 101
“7 27 However, other data show that immuno-therapy can still be effective against tumors with a paucity of mutations.”
Yi, S., Yan, Y., Jin, M., Bhattacharya, S., Wang, Y., Wu, Y., Yang, L., Gine, E., Clot, G., Chen, L., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153283 · Cited by 104
Kazanov, M. D., Roberts, S. A., Polak, P. P., Stamatoyannopoulos, J. A., Klimczak, L. J., Gordenin, D. A., & Sunyaev, S. R. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.077 · Cited by 103
“…cancer genomes against these epigenomic features can guide future research of mutagenic mechanisms in model systems and also help in dissecting the relative roles of mutagenesis and selection in the accumulation of cancer driver and passenger mutations (Lawrence et al., 2013; Polak et al., 2014).”
InfluentialSelf-citationA Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
Guenther, L. M., Dharia, N. V., Ross, L. S., Conway, A. S., Robichaud, A. L., Catlett, J. L., Wechsler, C. S., Frank, E. S., Goodale, A. B., Church, A. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0372 · Cited by 100
Self-citationXia, J., Jia, P., Hutchinson, K. E., Dahlman, K. B., Johnson, D., Sosman, J., Pao, W., & Zhao, Z. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0804 · Cited by 94
The Impact of Environmental and Endogenous Damage on Somatic Mutation Load in Human Skin Fibroblasts
Saini, N., Roberts, S. A., Klimczak, L. J., Chan, K., Grimm, S. A., Dai, S., Fargo, D. C., Boyer, J. C., Kaufmann, W. K., Taylor, J. A., et al. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006385 · Cited by 94
“We demonstrate that the mutation load in healthy cells (ranging from 581 to 12,743 mutations, Fig 3A) can be comparable to the mutation loads in some cancer genomes (median ~6000 mutations/cancer genome [61]) and the spectra as well as the correlation of base substitution density with epigenomic features resemble many…”
BackgroundSelf-citationKönig, K., Peifer, M., Fassunke, J., Ihle, M. A., Künstlinger, H., Heydt, C., Stamm, K., Ueckeroth, F., Vollbrecht, C., Bos, M., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000570 · Cited by 95
Hazen, J. L., Faust, G. G., Rodriguez, A. R., Ferguson, W. C., Shumilina, S., Clark, R. A., Boland, M. J., Martin, G., Chubukov, P., Tsunemoto, R. K., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.02.004 · Cited by 92
Consensus on precision medicine for metastatic cancers: a report from the MAP conference
Swanton, C., Soria, J., Bardelli, A., Biankin, A. V., Caldas, C., Chandarlapaty, S., de Koning, L., Dive, C., Feunteun, J., Leung, S.-Y., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw192 · Cited by 98
NLRC4 suppresses melanoma tumor progression independently of inflammasome activation
Janowski, A. M., Colegio, O. R., Hornick, E. E., McNiff, J. M., Martin, M. D., Badovinac, V. P., Norian, L. A., Zhang, W., Cassel, S. L., & Sutterwala, F. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86953 · Cited by 87
NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma
Brennan, K., Shin, J. H., Tay, J. K., Prunello, M., Gentles, A. J., Sunwoo, J. B., & Gevaert, O. (2017) · Scientific Reports · doi:10.1038/s41598-017-17298-x · Cited by 96
Metadata
- Authors
- Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., Kiezun, A., Hammerman, P. S., McKenna, A., Drier, Y., Zou, L., Ramos, A. H., Pugh, T. J., Stransky, N., Helman, E., Kim, J., Sougnez, C., Ambrogio, L., Nickerson, E., Shefler, E., Cortés, M. L., Auclair, D., Saksena, G., Voet, D., Noble, M., DiCara, D., Lin, P., Lichtenstein, L., Heiman, D. I., Fennell, T., Imielinski, M., Hernandez, B., Hodis, E., Baca, S., Dulak, A. M., Lohr, J., Landau, D.-A., Wu, C. J., Melendez-Zajgla, J., Hidalgo-Miranda, A., Koren, A., McCarroll, S. A., Mora, J., Lee, R. S., Crompton, B., Onofrio, R., Parkin, M., Winckler, W., Ardlie, K., Gabriel, S. B., Roberts, C. W. M., Biegel, J. A., Stegmaier, K., Bass, A. J., Garraway, L. A., Meyerson, M., Golub, T. R., Gordenin, D. A., Sunyaev, S., Lander, E. S., & Getz, G.
- Affiliations
- Broad Institute (US)
- National Institutes of Health (US)
- Harvard University (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Boston Children's Hospital (US)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Lander, Eric S.
- Getz, Gad
- ORCID
- Lawrence, Michael S.
- Polak, Paz
- Kryukov, Gregory V.
- Cibulskis, Kristian
- Sivachenko, Andrey
- Carter, Scott L.
- Stewart, Chip
- Mermel, Craig H.
- Roberts, Steven A.
- Hammerman, Peter S.
- McKenna, Aaron
- Drier, Yotam
- Zou, Lihua
- Pugh, Trevor J.
- Stransky, Nicolas
- Helman, Elena
- Kim, Jaegil
- Auclair, Daniel
- Saksena, Gordon
- Noble, Michael
- Lin, Pei
- Heiman, David I.
- Imielinski, Marcin
- Hernandez, Bryan
- Hodis, Eran
- Baca, Sylvan
- Dulak, Austin M.
- Lohr, Jens
- Landau, Dan-Avi
- Wu, Catherine J.
- Koren, Amnon
- McCarroll, Steven A.
- Mora, Jaume
- Crompton, Brian
- Winckler, Wendy
- Ardlie, Kristin
- Gabriel, Stacey B.
- Roberts, Charles W. M.
- Biegel, Jaclyn A.
- Stegmaier, Kimberly
- Bass, Adam J.
- Garraway, Levi A.
- Meyerson, Matthew
- Golub, Todd R.
- Gordenin, Dmitry A.
- Sunyaev, Shamil
- Lander, Eric S.
- Getz, Gad
- Venue
- Nature
- Published
- 2013-06-16
- Volume
- 499
- Issue
- 7457
- Pages
- 214-218
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3919509
- OpenAlex
- W2009720434
- Cited by
- 5,461
- References
- 30
- Citations by year
- 2026: 147 · 2025: 230 · 2024: 288 · 2023: 361 · 2022: 468 · 2021: 580 · 2020: 582 · 2019: 507 · 2018: 537 · 2017: 529 · 2016: 485 · 2015: 396 · 2014: 280 · 2013: 64
- FWCI
- 143.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (U24CA143845, T32CA009216, T32CA009172)
- National Institute of General Medical Sciences (T32GM007753)
- National Institute of Environmental Health Sciences (Z01ES065073)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Phylogenetic Studies
- Keywords
- mutational heterogeneity, cancer genes, MutSigCV, driver mutations, mutation frequency, lung cancer, lung squamous cell carcinoma, DNA replication timing, transcriptional activity
- MeSH terms
- False Positive Reactions, Humans, Lung Neoplasms, Mutation, Neoplasms, Oncogenes, Reproducibility of Results, Gene Expression, Genome, Human, Artifacts, Neoplasms, Squamous Cell, Sample Size, Genetic Heterogeneity, DNA Replication Timing, Exome, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.